Active Biotech Interim Report Q1 2023

May 4, 2023 08:30 (CEST) Regulatory

FIRST QUARTER IN BRIEF

  • Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30)
  • Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances
  • New preclinical data on naptumomab published

 
EVENTS AFTER THE END OF THE PERIOD

  • Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
  • New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023 (April 27)

FINANCIAL SUMMARY

SEK M Jan-Mar Full year
  2023 2022 2022
Net sales – – –
Operating profit/loss -11.8 -15.3 -57.9
Profit/loss after tax -11.5 -15.7 -58.4
Earnings per share (SEK) -0.04 -0.07 -0.25
Cash and cash equivalents (at close of period) 30.2 37.8 41.8

  
The report is also available at www.activebiotech.com

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-04 08:30 CEST.

Attachments

Ab Rapport 2023 Q1 En